Does site-of-care for oncology infusion therapy influence treatment patterns, cost, and quality in the United States?

Abstract

This study, in an older, predominantly Medicare Advantage oncology cohort, found differences by SOC in treatment patterns and cost, but not quality. Where differences were found, patients receiving care in the HO had shorter duration of therapy and fewer infusions for specific treatment regimens, but higher healthcare costs than those treated in a PO.

Real-World Utilization of Target- and Immunotherapies for Lung Cancer: A Scoping Review of Studies Based on Routinely Collected Electronic Healthcare Data

“…Screening of titles and abstracts allowed the selection of 131 potentially eligible studies. Among them, a total of 32 studies fulfilled the eligibility criteria and were finally included into the review [ 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 ]. No further studies were retrieved through a snowballing search.…”

“…Twenty-six out of 32 included studies used rcEHD from North America [ 27 , 28 , 29 , 30 , 31 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 ], two studies used data from Asia [ 24 , 32 ], three from Europe [ 26 , 42 , 55 ], and one from Australia [ 25 ]. Thirteen studies used record linkage of ≥1 type of data source [ 24 , 25 , 26 , 28 , 30 , 32 , 35 , 36 , 42 , 44 , 45 , 50 , 55 ], while 19 studies were based on one data source type only.…”

“…Thirteen studies used record linkage of ≥1 type of data source [ 24 , 25 , 26 , 28 , 30 , 32 , 35 , 36 , 42 , 44 , 45 , 50 , 55 ], while 19 studies were based on one data source type only. Among the latter, 14 studies used medical/health records only [ 29 , 33 , 34 , 37 , 41 , 43 , 46 , 47 , 48 , 49 , 51 , 52 , 53 , 54 ], four were based on administrative/claim data [ 31 , 38 , 39 , 40 ], and one study used data from cancer registries ( Table 1 ) [ 27 ]. Four studies [ 30 , 44 , 45 , 50 ] linked administrative/claim data with cancer registries.…”

“…The majority of the included studies concerned NSCLC patients (28 out of 32) [ 24 , 25 , 26 , 27 , 28 , 29 , 30 , 32 , 33 , 34 , 36 , 37 , 38 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 ], three studies included patients with unspecified lung tumor [ 31 , 39 , 55 ], and one study concerned neuroendocrine lung tumor [ 35 ]. Patients with SCLC were identified and included in one study, although the latter study primarily concerned NCSLC treatment ( Table 2 ) [ 27 ].…”

Digital Health Integration Assessment and Maturity of the United States Biopharmaceutical Industry: Forces Driving the Next Generation of Connected Autoinjectable Devices

“…Oncology is the major therapeutic focus in the injectable pipeline for 12 of the 15 companies evaluated in this study. Interestingly, research is being focused on subcutaneous delivery of oncology products, with trastuzumab researched extensively [37,[53][54][55]. With the discovery of more biologic therapeutic agents, we see more cancer patients being treated at home rather than in controlled inpatient settings.…”